Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Bevacizumab + Chemotherapy in EGFR Exon 20 Insertion NSCLC
NCT05751187Phase 2Active, not recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Jun 2023
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC), sponsored by Shanghai Chest Hospital. Started Jun 2023; status: active, not recruiting.
02
Drugs
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT05751187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05751187.